Interferons
| Zeile 7: | Zeile 7: | ||
{{tp|p=32483527|t=2020. Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a.|pdf=|usr=008}} | {{tp|p=32483527|t=2020. Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a.|pdf=|usr=008}} | ||
{{tp|p=32535509|t=2020. COVID-19, interferons, and depression: A commentary.|pdf=|usr=008}} | {{tp|p=32535509|t=2020. COVID-19, interferons, and depression: A commentary.|pdf=|usr=008}} | ||
| + | {{tp|p=32401715|t=2020. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.|pdf=|usr=009}} | ||
| + | {{tp|p=32526507|t=2020. Use of hydroxychloroquine and interferon alpha-2b for the prophylaxis of COVID-19.|pdf=|usr=009}} | ||
| + | {{tp|p=32445881|t=2020. Arbidol/IFN-alpha2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study.|pdf=|usr=009}} | ||
| + | {{ttp|p=32464097|t=2020. Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.|pdf=|usr=011}} | ||
| + | {{tp|p=32610043|t=2020. Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells.|pdf=|usr=011}} | ||
| + | {{tp|p=32532353|t=2020. Interferon beta-1a for COVID-19: critical importance of the administration route.|pdf=|usr=011}} | ||
| + | {{tp|p=32559285|t=2020. Interferon-beta 1a inhibits SARS-CoV-2 in vitro when administered after virus infection.|pdf=|usr=011}} | ||
| + | {{tp|p=32401712|t=2020. Interferon beta-1b for COVID-19.|pdf=|usr=009}} | ||
| + | {{tp|p=32587093|t=2020. Inhibition of SARS-CoV-2 by type I and type III interferons.|pdf=|usr=011}} | ||
| + | {{tp|p=32544867|t=2020. Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial.|pdf=|usr=011}} | ||
| + | {{tp|p=32544570|t=2020. Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon beta-1b.|pdf=|usr=011}} | ||
| + | {{tp|p=32574289|t=2020. Therapeutic Options for Coronavirus Disease 2019 (COVID-19) - Modulation of Type I Interferon Response as a Promising Strategy?|pdf=|usr=011}} | ||
| + | |||
| + | {{tp|p=32574262|t=2020. Interferon-alpha2b Treatment for COVID-19.|pdf=|usr=011}} | ||
Version vom 7. Juli 2020, 14:16 Uhr
32301957 ä. Weak Induction of Interferon Expression by SARS-CoV-2 Supports Clinical Trials of Interferon Lambda to Treat Early COVID-19
32275914 2020. Type 1 interferons as a potential treatment against COVID-19
32360182 2020. Antiviral activities of type I interferons to SARS-CoV-2 infection
32289152 2020. COVID-19 and emerging viral infections: The case for interferon lambda
32333818 2020. COVID-19: lambda interferon against viral load and hyperinflammation
21093489 2011. (x)Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model
32483527 2020. Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a.
32535509 2020. COVID-19, interferons, and depression: A commentary.
32401715 2020. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
32526507 2020. Use of hydroxychloroquine and interferon alpha-2b for the prophylaxis of COVID-19.
32445881 2020. Arbidol/IFN-alpha2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study.
| 32464097 2020. Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19. |
32610043 2020. Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells.
32532353 2020. Interferon beta-1a for COVID-19: critical importance of the administration route.
32559285 2020. Interferon-beta 1a inhibits SARS-CoV-2 in vitro when administered after virus infection.
32401712 2020. Interferon beta-1b for COVID-19.
32587093 2020. Inhibition of SARS-CoV-2 by type I and type III interferons.
32544867 2020. Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial.
32544570 2020. Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon beta-1b.
32574289 2020. Therapeutic Options for Coronavirus Disease 2019 (COVID-19) - Modulation of Type I Interferon Response as a Promising Strategy?
32574262 2020. Interferon-alpha2b Treatment for COVID-19.
